Gold Samuel, Taylor Jacob, Margulis Vitaly
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Curr Opin Urol. 2023 Mar 1;33(2):142-146. doi: 10.1097/MOU.0000000000001069. Epub 2023 Jan 9.
Surgery for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (TT) remains one of the most complex surgeries performed with high rates of associated complications and perioperative mortality. Surgical techniques and neoadjuvant therapies have an important role to play in improving outcomes. This review provides a narrative analysis of recent literature on patients with RCC and TT.
Several imaging techniques are emerging that may improve diagnostic staging of tumor thrombus level. Robotic approaches to surgical resection for all thrombi levels is feasible and safe, while longer term outcomes for higher level thrombi continues to mature. Early data on neoadjuvant immunotherapy and radiotherapy have shown improvements in complication rates and intermediate term oncologic outcomes.
Data suggests that neoadjuvant therapies and minimally invasive techniques may improve outcomes in patients undergoing surgical resection for RCC with tumor thrombus. Larger multiinstitutional series are needed to confirm the benefit of these techniques as well as the durable long term oncologic outcomes.
对伴有下腔静脉瘤栓(TT)的肾细胞癌(RCC)进行手术仍然是最复杂的手术之一,相关并发症发生率和围手术期死亡率都很高。手术技术和新辅助治疗在改善治疗效果方面发挥着重要作用。本综述对近期有关RCC合并TT患者的文献进行了叙述性分析。
几种新兴的成像技术可能会改善肿瘤栓子水平的诊断分期。机器人辅助对所有栓子水平进行手术切除是可行且安全的,而更高水平栓子的长期治疗效果仍在不断完善。新辅助免疫治疗和放疗的早期数据显示并发症发生率和中期肿瘤学结局有所改善。
数据表明,新辅助治疗和微创技术可能会改善接受RCC合并肿瘤栓子手术切除患者的治疗效果。需要更大规模的多机构系列研究来证实这些技术的益处以及持久的长期肿瘤学结局。